MIRASOL: A randomized, open-label, phase 3 study of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FRα) expression (297) - Moore, Kathleen; Konecny, Gottfried; Martin, Lainie; Floquet, Anne; O'Malley, David; Colombo, Nicoletta; Mantia-Smaldone, Gina; Banerjee, Susana; Gilbert, Lucy; de Gregorio, Nikolaus; Tromp, Jacqueline; Wang, Jiuzhou; et al. (Gynecologic Oncology, 2022)